Marshall Investment Management LLC Makes New $69,000 Investment in MannKind Co. (NASDAQ:MNKD)

Marshall Investment Management LLC acquired a new position in shares of MannKind Co. (NASDAQ:MNKD) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 11,000 shares of the biopharmaceutical company’s stock, valued at approximately $69,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. raised its holdings in MannKind by 22.3% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 9,946 shares of the biopharmaceutical company’s stock worth $62,000 after purchasing an additional 1,816 shares during the last quarter. Beirne Wealth Consulting Services LLC bought a new stake in shares of MannKind in the 4th quarter valued at about $66,000. Quantinno Capital Management LP bought a new stake in shares of MannKind in the 3rd quarter valued at about $85,000. Foundations Investment Advisors LLC bought a new stake in shares of MannKind in the 3rd quarter valued at about $93,000. Finally, National Bank of Canada FI increased its stake in shares of MannKind by 14.8% in the 3rd quarter. National Bank of Canada FI now owns 21,553 shares of the biopharmaceutical company’s stock valued at $136,000 after acquiring an additional 2,783 shares during the last quarter. 49.55% of the stock is owned by institutional investors.

MannKind Stock Performance

NASDAQ MNKD opened at $5.77 on Friday. The business has a 50 day simple moving average of $6.06 and a 200 day simple moving average of $6.27. MannKind Co. has a 52-week low of $3.47 and a 52-week high of $7.63. The stock has a market cap of $1.59 billion, a price-to-earnings ratio of 82.36 and a beta of 1.28.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on MNKD. StockNews.com cut MannKind from a “buy” rating to a “hold” rating in a research note on Saturday, December 7th. Royal Bank of Canada raised MannKind from a “sector perform” rating to an “outperform” rating and upped their price target for the company from $7.00 to $10.00 in a research note on Thursday, December 19th. Wedbush began coverage on MannKind in a research note on Monday, February 10th. They issued an “outperform” rating and a $11.00 price target for the company. Finally, Wells Fargo & Company began coverage on MannKind in a research note on Friday, December 20th. They issued an “overweight” rating and a $9.00 price target for the company. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $9.21.

MannKind Profile

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.